Book Details

Internet Resource: Please Login to download book

The objective of this study was to develop the matrix of transdermal drug delivery system (TDDS) of ondansetron hydrochloride (ODH), in which ondansetron is the first serotonin subtype 3 receptor antagonist indicated for the treatment and/or prophylaxis of postoperative, chemotherapy or radiotherapy induced emesis. It has been proven efficient and safe to treat such symptoms, by using in vitro drug release study and evaluate the effect of eucalyptus oil and different percentage of carbopol 940. The result of drug release decreased by increasing the percentage of carbopol 940 which achieved the purpose of the study by prolonging the release of the ondansetron . The patch provides a means to reduce the side effects associated with its oral therapy, avoidence of the first-pass metabolism and minimize inconsistency in absorption across GIT. Various types of transdermal patches are used to incorporate the active ingredients into the circulatory system via skin.